

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8281528

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
VENTUS THERAPEUTICS, INC.	11/07/2023
RECEIVING PARTY DATA	
Name:	VENTUS THERAPEUTICS U.S., INC.
Street Address:	100 BEAVER STREET, SUITE 201
City:	WALTHAM
State/Country:	MASSACHUSETTS
Postal Code:	02453
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	63420930
Application Number:	63443874
Application Number:	17704983
PCT Number:	US2023064967
Application Number:	18190920
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6179372300
Email:	jsteinfield@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVENUE NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	VNTS-008 PROV PCT 2US
NAME OF SUBMITTER:	CHRISTINE E. DUNNE
SIGNATURE:	/Christine E. Dunne/
DATE SIGNED:	11/16/2023
Total Attachments: 6	

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page1.tif

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page2.tif

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page3.tif

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page4.tif

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page5.tif

source=VNTS-008-ASSIGNMENT-VTI-TO-VENTUS-US#page6.tif

PATENT

REEL: 065587 FRAME: 0910

**ASSIGNMENT OF PATENT RIGHTS
(Company to Company)**

Ventus Therapeutics, Inc., a corporation having its principal place of business at 7150 Frederick-Banting, Montreal, QC H4S 2A1, CANADA (herein referred to as "Assignor") owns the entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth below, as well as any invention(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

SEE SCHEDULE A

WHEREAS, Ventus Therapeutics U.S., Inc., a corporation having its principal place of business at 100 Beaver Street, Suite 201, Waltham, MA 02453, (the "Assignee"), its successors, legal representatives, and assigns, is desirous of acquiring the Assignor's entire right, title, and interest in and to said invention(s), said application(s) for patent and/or registered design, and said patent(s); the right to file applications for patent and/or registered design of the United States or other countries on said invention(s); the entire right, title and interest in and to any application(s) for patent and/or registered design, and patent(s) of the United States or other countries claiming priority to, and/or benefit of, these applications and patents; the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) for patent and/or registered design and said patent(s); and the entire right, title, and interest in and to any and all Letters Patent or Patents and/or registered design(s), United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns Assignor's right, title, and interest in and to:

- (a) said invention(s);
- (b) said application(s) for patent;
- (c) said patent(s);
- (d) the right to file applications for patent and/or registered design of the United States or other countries on said invention(s), including all rights under the Hague Convention, the Paris Convention for the

Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

- (e) any application(s) for patent and/or registered design of the United States or other countries claiming the invention(s);
- (f) any application(s) for patent and/or registered design of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent and/or registered design identified above or any application(s) for patent claiming the invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (g) the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) for patent and/or registered design and said patent(s) identified in the preceding paragraphs (b)-(f) and of any and all patent(s) and/or registered design(s) granted based thereon in the United States and in all other countries; and
- (h) any and all Letters Patent or Patents and/or registered design(s), United States or foreign, to be obtained for said invention(s), said application(s) for patent and/or registered design, and said patent(s), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said invention(s), said application(s), and said patent(s), and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignor also hereby represents that, except for said prior agreement, if applicable, the Assignor has not previously sold, transferred, or encumbered any part of Assignor's right, title, and interest in the Invention(s);

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention(s), said application(s), said registered design(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor waives all rights to challenge the validity of said invention(s) in the United States and its territorial possessions and in all foreign countries and of all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention(s) by said application or any continuation, continuation-in-part, divisional, renewal, substitute, or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted;

AND the Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided the application number, file date, attorney docket number, assignment recordation date, and Reel/Frame No(s). of the Patent Application(s) and/or Letters Patent(s) identified herein when known;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the use and behalf of the Assignee, its successors, legal representatives, and assigns;

AND Assignor(s) and Assignee(s) understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.

For and on behalf of ASSIGNOR:

Date: November 7, 2023

By: Christine Ha

Name: Christine Ha
Title: Chief Financial Officer
Company: Ventus Therapeutics, Inc.

By signing, I confirm that I am entitled to sign legally binding acts on behalf of Ventus Therapeutics, Inc.

My position in Ventus Therapeutics, Inc. is: Chief Financial Officer

Witness:

Jessie Haigh
Signature

11-7-23
Date

Jessie Haigh
Printed Name

Witness:


Heather Lokys
Signature

11/7/2023
Date

Heather Lokys
Printed Name

For and on behalf of ASSIGNEE:

Date: 11/7/2023


By: 

Name: Robin Weatherhead, Ph.D., J.D.
Title: V.P., Intellectual Property & Legal
Company: Ventus Therapeutics U.S., Inc.

By signing, I confirm that I am entitled to sign legally binding acts on behalf of Ventus Therapeutics U.S., Inc.

My position in Ventus Therapeutics U.S., Inc. is: V.P., Intellectual Property & Legal


Witness:


Signature

11/7/2023
Date

Heather Lokys
Printed Name

Witness:


Signature

11-7-23
Date

Jessie Haight
Printed Name

SCHEDULE A

Application No.	Application Date	Title/Mark	Country
17/704,983	3/25/2022	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	United States of America
17/984,018	11/9/2022	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	United States of America
63/420,930	10/31/2022	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	United States of America
63/443,874	2/7/2023	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	United States of America
P20230100736	3/27/2023	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	Argentina
112111280	3/24/2023	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	Taiwan
18/190,920	3/27/2023	PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	United States of America
PCT/US2023/064967	3/24/2023	PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES	Patent Cooperation Treaty